5292-69-3

Basic information

• Product Name: Morpholine, 4-(6-methyl-1-cyclohexen-1-yl)-
• CAS NO: 5292-69-3
• Molecular Formula: C11H19NO
• Molecular Weight: 181.278
• Mol File: 5292-69-3.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: Morpholine, 4-(6-methyl-1-cyclohexen-1-yl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Morpholine, 4-(6-methyl-1-cyclohexen-1-yl)-(5292-69-3)
• EPA Substance Registry System: Morpholine, 4-(6-methyl-1-cyclohexen-1-yl)-(5292-69-3)

Safety Data

• Hazardous Substances Data: 5292-69-3(Hazardous Substances Data)

Upstream product

• 110-91-8 morpholine 
• 583-60-8 2-Methylcyclohexanone 

Downstream Products

• 64760-74-3 cis-N-(2-methylcyclohexyl)morpholine 
• 64760-75-4 trans-N-(2-methylcyclohexyl)morpholine 
• 1208-47-5 6-benzylidene-2-methylcyclohexan-1-one 
• 86822-52-8 4-(2-Methyl-cyclohexylidene)-morpholin-4-ium; chloride 
• 52456-90-3 6-methyl-2-hydroxycyclohexanone 
• 4591-60-0 6-Methyl-2-(2-nitroethyl)-cyclohexanon 
• 5292-70-6 benzoyloxy-(3-methyl-2-morpholin-4-yl-cyclohex-2-enylidene)-phenyl-methane 

Relevant articles and documents

PHARMACEUTICAL COMPOSITION CONTAINING FUSED HETERO-RING DERIVATIVE

The present invention provides a compound which indicates a histamine H4 receptor modulating activity.A compound represented by a formula (I): wherein A ring is a ring represented by the following formula: wherein R1 is substituted or unsubstituted alkyl, etc., W is -O-, etc., n is an integer of 0 to 6; X is N(R7)- or -O-; R7 is hydrogen, substituted or unsubstituted alkyl, etc.; Y is-C(R8)= or -N=; R8 is hydrogen, substituted or unsubstituted alkyl, etc.; Z is =O, =S, etc.; B ring is a ring represented by the following formula wherein R10 is each independently substituted or unsubstituted alkyl, halogen, hydroxy, substituted or unsubstituted alkyloxy, substituted or unsubstituted amino; R11, R12a and R12b are each independently hydrogen or substituted or unsubstituted alkyl, etc.; p is an integer of 0 to 4, or its pharmaceutically acceptable salt, or a solvate thereof.The present invention provides a compound which indicates a histamine H4 receptor modulating activity. A compound represented by a formula (I): wherein A ring is a ring represented by the following formula: wherein R 1 is substituted or unsubstituted alkyl, etc., W is -O-, etc., n is an integer of 0 to 6; X is N(R 7 )- or -O-; R 7 is hydrogen, substituted or unsubstituted alkyl, etc.; Y is-C(R 8 )= or -N=; R 8 is hydrogen, substituted or unsubstituted alkyl, etc.; Z is =O, =S, etc.; B ring is a ring represented by the following formula wherein R 10 is each independently substituted or unsubstituted alkyl, halogen, hydroxy, substituted or unsubstituted alkyloxy, substituted or unsubstituted amino; R 11 , R 12a and R 12b are each independently hydrogen or substituted or unsubstituted alkyl, etc.; p is an integer of 0 to 4, or its pharmaceutically acceptable salt, or a solvate thereof.